Hollis-Eden Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations.SAN DIEGO -- Hollis-Eden Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :HEPH HEPH Hollis Eden Pharmaceuticals, Inc ) today announced that it is scheduled to make presentations at the following conferences: UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , at 9:00 a.m. Eastern, September 29, 2004. American Society of Therapeutic Radiology and Oncology Annual Meeting in Atlanta, Ga., October 3-7, 2004. The Company plans to present updated data on its radiation protection drug candidate, NEUMUNE(TM), and will issue a news release in conjunction with the meeting. BIO Emerging Company Investor Forum in San Francisco, at 1:50 p.m. Eastern (10:50 a.m. Pacific), October 15, 2004. Rodman & Renshaw Techvest Annual Healthcare Conference in New York City, at 10:25 a.m. Eastern, October 28, 2004. Live webcasts will be available from the investor conferences, and may be accessed under "Event Calendar" on the Investors section of Hollis-Eden's website at www.holliseden.com. Webcasts will be archived at the Company's website for 30 days. Hollis-Eden Pharmaceuticals, Inc., a development-stage pharmaceutical company based in San Diego, is a world leader in the development of a new class of investigational drugs known as Immune Regulating Hormones (IRHs). The goal of IRH IRH Institute for Reproductive Health IRH Inverclyde Royal Hospital IRH Institute for Research in Human Happiness IRH Inspection Requirements Handbook therapy is to direct, through controlling gene expression, the production of key cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. and enzymes that re-regulate immune and metabolic functions toward homeostasis homeostasis Any self-regulating process by which a biological or mechanical system maintains stability while adjusting to changing conditions. Systems in dynamic equilibrium reach a balance in which internal change continuously compensates for external change in a feedback , a profile that could be useful in a wide variety of diseases. Hollis-Eden has a number of investigational IRHs under development, including NEUMUNE(TM), which the Company is co-developing with the U.S. military for use in protection from radiation injury, IMMUNITIN(TM), which has shown activity in a variety of infectious diseases, including HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , tuberculosis and malaria, as well as additional compounds for protection from chemotherapy and other conditions of immune dysregulation. In addition, Hollis-Eden is developing PHOSPHONOL(TM), a non-IRH drug candidate, for providing protection against DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. mutations from radiation exposure and chemotherapy treatment. For more information on Hollis-Eden, contact the Company's website at www.holliseden.com. This press release contains forward-looking statements concerning the potential and prospects of the Company's drug discovery program and its drug candidates. Any statement describing a goal, expectation, intention or belief of the Company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including the failure to successfully complete preclinical or clinical studies, the Company's ability to obtain additional funding and required regulatory approvals, the ability to successfully commercialize the Company's products, the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others, the development of competitive products by other companies and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion